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Abstract 
Bacillus sp. present a great diversity and a high productivity of protease. 
The group of Biotechnology Department of the Universidade dos Açores has a 
microbial isolates bank which includes about 1600 isolates of Bacillus sp. Some 
of the biggest potential thrombolytic enzymes are isolated from Bacillus sp. 
(streptokinase and natokinase). In this work we tested 79 isolates, previous 
tested to find a thrombolytic enzyme. 
The 79 isolates were tested for proteolytic activity in agar casein plate. 
Then the fibrinolytic activity and the thrombolytic activity of selected isolates were 
tested. Was determinate the group species of the bacterial isolates with higher 
activity and were selected 1 isolate from each group. The optimal pH and the 
optimal temperature of the extracellular protease produced by 11 isolates from 
Bacillus sp. were determinate also.  
A hemolytic test was made to the enzymes with a higher thrombolytic 
activity. After we check for fibrinolytic, thrombolytic and hemolytic activity were 
selected 2 isolates. These 2 isolates were tested for aPTT and PT activity, for 
plasminogen activator activity, fibrinogenolytic activity and euglobulin lysis time. 
1 bacterial enzyme was selected for biochemical characterization and 
purification. 
From the 79 isolates with high proteolytic activity 27 were chosen by 
their high activity in pH 7.5 and 37˚C. From these 27 bacterial isolates 11 were 
spotted with fibrinolytic activity and thrombolytic activity (just 6% of the initial 79 
isolates). 4 of these enzymes (S97B, S88A, S178C and 99D) belongs to Bacillus 
cereus group, 4 belongs to Bacillus mycoides group (S101C, S115C, S26A and 
S62A) and 3 belongs to Bacillus subtilis group (S157E, S122C and S150C). Were 
selected 2 isolates from the Bacillus mycoides group (S115C and S101C) 
because they didn’t presented hemolytic activity. The isolate S115C didn’t 
interfere with aPPT test neither with PT test, otherwise S101C increase the aPPT, 
interfering with the normal coagulation time. Was also evidence that S101C is a 
plasminogen activator (t-PA) and S115C is not. Moreover S115C presented more 
than 10x fibrinolytic activity then S101C, thus enzyme S115C was selected for 
biochemical characterization and purification. Biochemical characterization 
 
 
2 
 
showed that S115C was a high inhibited by Benzamidine, STI, Chymostatin and 
PTCK indicating that S115C is a chymotrypsin-like serine protease. Suc-Ala-Ala-
Pro-Phe-pNa was a specific substrate which indicates chymotrypsin activity. The 
activity of these enzyme was highly enhanced by Mn and slightly enhanced by 
Na and Ca2. This enzyme was inhibited by metal ions Mg2+, Cu+ and Ni2+. 
The zymogram of the purified enzyme revel a digestion band higher 
than 135 kDa and another band at 75kDa. SDS-page of purified fraction revel 2 
bands one at 75 kDa and another at 140kDa. The SDS-page bands were cut and 
sent to analysis of mass spectrometry (Ms/Ms). 
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I Introduction 
The blood coagulation cascade is initiated when subendothelial tissue 
factor is exposed/expressed to the blood flow following either the damage or 
activation of the endothelium. This may occur as a consequence of the 
perforation of the vessel wall or activation of endothelium by chemicals, 
cytokines, or inflammatory processes (Camera, M. et al, 1999). 
When it occurs in the heart, clots may cause blockage of blood flow to 
the muscle tissue (myocardium), cutting the supplemental oxygen to tissue and 
causing cell death. With increasing age of the organism, the production of these 
enzymes begins to decrease, making it more susceptible to blood clotting. This 
mechanism can lead to myocardial infarction or cerebral, and other pathological 
conditions. Since endothelial cells exist all over the body, such as arteries, veins 
and lymphatic system, the deficit in the production of thrombolytic enzymes can 
lead to the development of thrombotic conditions virtually anywhere in the body.. 
Thrombotic diseases typically include cerebral hemorrhage, myocardial infarction 
and cerebral, and angina pectoris but also includes other diseases caused by 
blood vessels with low flexibility in cases of senile dementia or patients with 
diabetes. (Kotb, 2012). 
1. Blood Coagulation 
The coagulation process is currently a matter very well studied and 
continues to be the subject of research and new discoveries. 
Several proteins involved in the clotting process and inhibitors have 
been discovered and new interactions between these system components. 
Increased knowledge on the coagulation process enabled the development of 
new diagnostic coagulation tests, and the discovery of new anti-thrombotic and 
hemostatic drugs (Bombeli and Spahn, 2004). 
The coagulation process under normal physiological conditions is 
initiated through the extrinsic pathway, which is dependent on a tissue factor, also 
called thromboplastin or factor III (Butenas et al., 2000). 
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In the initiation phase of coagulation, damaged tissue releases the 
tissue factor (TF), which in turn binds to, factor VIIa, already present in blood and 
forms the factor VIIa–tissue factor complex (extrinsic factor Xase), which 
activates the zymogens factor IX to factor IXa and factor X to factor Xa The limited 
amounts of the serine protease factor Xa produced generate picomolar 
concentrations of thrombin (factor IIa), which partially activates platelets and 
cleaves the pro-cofactors factor V and factor VIII generating the active cofactors 
factor Va and factor VIIIa, respectively (Bombeli and Spahn, 2004).  
Factor VIIIa forms the intrinsic factor Xase complex with the serine 
protease, factor IXa, and activates factor X. Factor Xa forms the prothrombinase 
complex with the cofactor, factor Va, which is the primary activator of 
prothrombin. The produced thrombin amplifies its own generation by activating 
factor XI and completing activation of platelets and factors V and VIII (Pieters, J. 
et al, 1989). Thrombin also cleaves fibrinogen and factor XIII to form the insoluble 
crosslinked fibrin clot. The procoagulant processes are attenuated by a variety of 
inhibitors, which inactivate either serine proteases or cofactors (Bombeli and 
Spahn, 2004). Except for the first two steps in the intrinsic pathway, calcium ions 
are required for promotion or acceleration of all the blood-clotting reactions (Jesty 
and Beltrami, 2005). 
The activation of the TF: VII by factor Xa is the main positive feedback 
mechanism of coagulation process. When the TF is available in the plasma, this 
binds with inactive factor VII to form VIIa form. Most of the available TF binds to 
the inactive form of FVII, giving rise to the TF: VII, this is because the levels of 
FVIIa medium are low in plasma, about 0.5% of the total FVII, resulting in a small 
proportion of the complex TF: VIIa formed, but sufficient to activate FX and the 
feedback process occurs which leads to the conversion of TF:VII to TF: VIIa. The 
FVIII activation by thrombin is another positive feedback step. The regulatory 
factor VIII is a cofactor for factor IXa, but this circulates the blood in the inactive 
form. And the FIXa does not act in the coagulation cascade while the FVIII is in 
the inactive form (Jesty and Beltrami, 2005). Furthermore thrombin activates 
factor V cofactor to accelerate the activation of FII (prothrombin) at FXa and FXIa 
to still FXI leading to increase FIXa (Bombeli and Spahn, 2004). The following 
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stage is called propagation and is characterized by keeping the production of 
thrombin, in order to ensure sufficient blood clot formation, by converting 
fibrinogen into fibrin.  
 
Figure 1 Coagulation cascade: the conversion of fibrinogen into fibrin is triggered by 
thrombin and calcium. (Jockenhoevel, et al.,2011) 
 
There is the phase of clot stabilization, where the thrombin reaches 
higher levels and are sufficient to activate FXIII (one transglutaminase) 
establishing covalent bonds between the soluble fibrin monomers to yield an 
insoluble mesh stable fibrin. In this phase the inhibitor by thrombin activatable 
fibrinolysis (TAFI) protects the clot fibrinolysis attack (Bombeli and Spahn, 2004). 
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At the end of the coagulation cascade, factor XIIIa creates covalent 
bonds between fibrin molecules, which precipitate and form a clot, which fibers 
are more resistant to the activity proteolytic and mechanical disruption. The 
presence of Factor XIII is highly important because the fibrin fibers need to be 
stabilized to form a strong structure capable of preventing loss of blood circulatory 
system (Standeven et al., 2007). 
Fibrin is organized by two chains of fibrinogen, crosslinked, α  and γ and 
non-crosslinked chain, β (McDonagh, et al., 1972). Factor XIIIa is capable of 
generating structures containing various combinations of crosslinks between γ 
and α chains of fibrin, giving a high resistance to fibrinolysis. It is not yet fully 
known the effect of different cross-linking the fibrin clot formation, however it is 
known that increasing the rigidity of blood clots is attributed to crosslinks between 
α chains (Collet et al., 2005). 
2. Fibrinolysis 
Fibrinolysis is a process that prevents blood clots from growing and 
becoming problematic. The main enzyme in this process is plasmin, a proteolytic 
enzyme whose sole role is to dissolve fibrin. Plasmin is produced in an inactive 
form, plasminogen, in the liver. Plasminogen cannot cleave fibrin. Instead, it is 
incorporated into the clot when it is formed and then activated into plasmin later. 
Plasminogen is activated to plasmin by tissue plasminogen activator (t-PA). The 
tissue plasminogen activator (t-PA), which is released by the endothelium, in the 
presence of fibrin acts as a cofactor and catalyze the conversion of glu-
plasminogen (GPG) to glu-plasmin (GPN). t-PA activates plasminogen at a very 
low rate. (Dobrovolsky and Titaeva, 2002). 
Plasmin digests fibrin fibers and some other protein coagulants such as 
fibrinogen, Factor V, Factor VIII, prothrombin, and Factor XII. Therefore, 
whenever plasmin is formed, it can cause lysis of a clot by destroying many of 
the clotting factors, thereby sometimes even causing hypocoagulability of the 
blood (Muszbek, et al., 2011). 
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This process begins digestion of fibrin (FN) by catalyzing cleavage after 
specific arginine and lysine residues in α, β, and γ chains of fibrin. Fibrin is 
modified to FN’ a form that has in its structure carboxyl terminal lysine residues, 
which promote the binding of tissue-type plasminogen activator (t-PA) and GPg 
to fibrin. These reactions are catalyzed by GPn and LPn. LPg is approximately 
20-fold better than GPg as a substrate for tPA-catalyzed formation of plasmin 
(LPn). Thus, modification of FN to FN′ represents positive feedback in the 
fibrinolytic cascade, somewhat similar to that represented by thrombin-catalyzed 
activation of factors V and VIII in the coagulation cascade by thrombin (Nesheim, 
2003).In addition, thrombomodulin of endothelial cells is important in the 
regulation of the balance between the two systems, it is able to convert thrombin 
anticoagulant enzyme, directing it to the activation of protein C and can also 
convert thrombin for an enzyme antifibrinolytic, directing it to the activation of 
TAFI (Nesheim, 2003). 
3. Pathologies related to fibrinolysis 
The high expression of these activators, leads to the appearance of 
abnormal bleeding, but they are very rare conditions (Booth et al., 1983). 
Excessive production activator plasminogen activator (u-PA) within the alpha-
granules of platelets, is related to Quebec syndrome, an extremely rare 
autosomal dominant hemorrhagic disease (Diamandis et al, 2009; Veljkovic et al, 
2009). Several studies have associated high levels of PAI -1 with venous or 
arterial thrombosis and the risk of septic shock and multiple organ failure 
(Sanchez Miralles et al, 2002; Williams, 1989). The change of plasminogen 
activators also appears to be linked to the onset of diseases. There are sporadic 
reports on t-PA deficient patients with thrombosis (Brandt, 2002). Moreover, the 
high expression of these activators, leads to the appearance of abnormal 
bleeding, but they are very rare conditions (Booth et al., 1983). 
The plasminogen deficiency in both the heterozygous and homozygous 
form, is related to the appearance of thrombosis in the presence of other genetic 
defects, such as mutation of factor V Leiden (Demarmels Biasiutti et al., 1998). 
Other pathologies related to a severe deficiency in plasminogen can lead to the 
development of Woody conjunctivitis, a rare ocular disease characterized by the 
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formation of fibrin rich pseudomembranes essentially the tarsal conjunctiva 
(Seregard and Schuster, 2003). 
4. Thrombolytic Therapy 
In general, there are three thrombolytic therapy options for patients, by 
administration of anticoagulants and antiplatelet agents, and finally through the 
use of fibrinolytic enzymes. 
Anticoagulants act by blocking one or more stages of the coagulation 
cascade that culminates in the formation of fibrin. Some drugs used can also act 
by inhibiting synthesis of coagulation factors while others increase the 
anticoagulant activity which occurs naturally in blood and prevent the formation 
of platelet stopper (Kotb, 2012). Heparin is a example of an anticoagulant, whose 
main purpose lies in its inhibition of thrombin and factor IIa and Xa in the 
coagulation cascade. In addition has a short half-life, it is associated with 
bleeding, osteoporosis, alopecia, thrombocytopenia and hypersensitivity 
(Fitzmaurice et al., 2002). Warfarin is an anticoagulant that inhibits coagulation 
interfering with the incorporation of vitamin K dependent coagulation factors 
Vitamin K, including factors II, VII, IX and X. (Kotb, 2012). 
Antiplatelet agents are used to prevent clot formation or prevent it from 
becoming larger. Antiplatelet drugs such as dipyridamole, clopidogrel and 
ticlopidine act through inhibition of platelet activating factor and collagen. Aspirin 
is the most widely used antiplatelet drug and its mode of action is through 
inhibition of platelet aggregation. (Patrono, et al., 2002). 
 
4.1. Enzyme Therapy 
Different enzymes purified from various microbial, animal and plant 
sources have been used in varied ranges of physiological, medicinal, and 
industrial applications. Among them, fibrinolytic enzyme is one which has a 
significant medical applications for the treatment of cardiovascular diseases 
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(CVDs) caused by intravascular thrombosis. CVDs are the leading cause of death 
throughout the world (Mender et al, 2011). 
Enzymes are the bio-catalysts playing an important role in all stages of 
metabolism and biochemical reactions. Unlike heparin and warfarin, fibrinolytic 
enzymes promote lysis of pre-existing thrombus. Nowadays the biggest producer 
of fibrinolytic enzymes are Bacillus spp (Annex Figure 1). Depending on the mode 
of action of these enzymes, they may be classified into two types, plasminogen 
activators (PA) and enzymes plasmin type which degrade directly fibrin, which in 
turn leads to rapid and complete destruction of thrombus (Kotb, 2013). 
The group of plasminogen activator enzymes include streptokinase, 
Urokinase (Duffy, 2002), and tissue plasminogen activator (t-PA) genetically 
modified (Lijnen and Collen, 2004). Urokinase is the best Known human 
plasminogen activator. This enzyme is capable of catalyzing the conversion of 
the inactive zymogen plasminogen to the active proteinase plasmin, Urokinase is 
extracted from urine (Andreasen, et al., 1997). Urokinase is too expensive and 
after intravenous administration there is a significant risk of hemorrhagic (Yang, 
et al., 2012). 
Streptococcus hemolyticus and Staphylococcus aureus produce 
staphylokinase and streptokinase respectively, where both are used in 
thrombolysis (Collen and Lijnen, 1994). Streptokinase can potentiate the body’s 
own fibrinolytic pathways by converting plasminogen to plasmin. The 
streptokinase is an effective thrombolytic agent of bacterial (streptococci). This 
enzyme enhances the fibrinolytic pathway by converting plasminogen to plasmin.  
t-PA produced by recombinant DNA technology, have the same 
properties of the molecule that activates the endogenous fibrinolytic system, and 
therefore do not develop allergic responses and is considered more specific for 
the lysing of the clot (Mine et al., 2005)  
There is a large set of fibrinolytic enzymes were discovered in particular 
of the genus Bacillus sp isolated from traditional fermented foods (Peng et al., 
2005). Natokinase is an enzyme that is extracted from Natto, a fermented soy 
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bean. It functions include directly degrading a fibrin (the main component of 
thrombi), activating pro-Urokinase (precursor for Urokinase that is a thrombolytic 
enzyme in the body) and increasing the amount of tissue plasminogen activator 
(t-PA) that produces a thrombolytic enzyme, plasmin. In addition, recent research 
has revealed that Nattokinase has a function of degrading plasminogen activator 
inhibitor, PAI-1 and reducing the euglobulin lysis time, and therefore, it has a 
function of improving the thrombolytic activity. Furthermore, the reduction of 
blood pressure has also been confirmed (Urano et al., 2001). An additional study 
indicates that nattokinase can also be purified from TKU015 culture supernatant 
of strain Pseudomonas sp. isolated from soil which has high activity on fibrin 
(Wang et al., 2009). 
According to Suzuki et al. (2003), a supplementary diet with natto is 
related to the shortening of the euglobulin lysis time, which is an indicator of the 
total intrinsic plasma fibrinolytic activity. Simultaneously, this enzyme does not 
prolong the clotting time, indicating that it may be used as a safe food 
supplement, has no unwanted side effects. 
More recently was discovered in B. amyloliquefaciens subtilisin DC-4 of 
Chinese fermented soybean designated Douchi (Peng et al., 2003), this enzyme 
can activate t-PA and it can dissolve fibrin directly (Yang, et al. 2012). Unlike 
Urokinase and streptokinase has no side effect and it has no toxic. Douchi like 
Natokinase has a convenient oral administration, and stability in the 
gastrointestinal tract (Sumi et al., 1990).  
 
 
These enzymes also have some negative aspects such as the low 
specificity of active centers, which leads to adverse effects including 
gastrointestinal bleeding (Turpie et al., 2002); systemic fibrinogenolysis 
accompanied by bleeding problems is also often found as well as neural 
complications (Caramelli et al., 1992), intracranial hemorrhages (Kase et al., 
1992). 
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The limited efficacy and undesired side effects of these thrombolytic 
agents pose problems for their clinical application. Much research is made in 
order to overcome these problems by seeking increasing the thrombolytic activity 
of the target or for improving targeting of these proteins on the clots. Furthermore 
both streptokinase and urokinase dependent and act by the activation of 
plasminogen to plasmin (indirect action), making it important to direct the further 
research for the discovery of novel agents that are able to act directly on fibrin 
(Caramelli et al., 1992). 
  
4.2. Proteases 
The fibrinolytic enzymes are mostly proteases. These catalyze hydrolysis 
reactions on proteins and act specifically in the interior peptide bonds. Most living 
cells produce different types of proteases, but most of it is produced by 
microorganisms. 
Proteases are subdivided into two groups depending on their mode of 
action, are called exopeptidases or endopeptidases. The exopeptidases cleave 
peptide bonds near the amino or carboxy terminus of the substrate, whereas 
endopeptidases cleave peptide bonds distant end group of the substrate. Based 
on the functional group present at the active site of the proteases, they can be 
classified into four families: the serine proteases, aspartic proteases, cysteine 
proteases and metalloproteases. Fibrinolytic proteases are for the most serine or 
metalloproteases and have great importance in the food, pharmaceutical and 
residual maintenance industry (Kotb, 2012). 
More than one third of all the known proteolytic enzymes belong to the 
group of serine proteases, distributed in 40 families. Serine proteases are 
characterized by the presence of a catalytic triad composed of the residues of the 
amino acids aspartic acid, serine and histidine. They are present in eukaryotes, 
prokaryotes, in archaea and viruses, and participate in diverse physiological 
processes, including proteases of the digestive system (trypsin and 
chymotrypsin), immune system (complement factors B, C and D), enzymes 
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involved in coagulation (factors VIIa, IXa, Xa and XIIa), fibrinolytic enzymes 
(urokinase, tissue plasminogen activator and plasmin) and reproductive system 
(acrosin).   
The trypsin-like proteases are the most abundant group of serine 
proteases. For a long time just two groups of known serine proteases, the trypsin-
like enzymes (clan PA) exhibit a double b-barrel fold, whereas the subtilisin-like 
enzymes (clan SB) have a parallel b-sheet structure. The peptidases of clan SC, 
which were discovered considerably later (Rawlings, et al., 1991), display an a,b-
hydrolase fold with the same catalytic triad as found with the classic serine 
peptidases, chymotrypsin and subtilisin (serine, histidine and aspartic acid), but 
with an opposite handedness. However, in recently identified clans (SE, SF, SH, 
SJ, SK, SP, SR) the members of the catalytic triad and thus the mechanism of 
action changed to some extent. (Polgar, 2005). 
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II Materials and Methods 
1. Bacterial growth and enzyme extract preparation 
 The group of Biotechnology Department of the Universidade dos 
Açores have 1600 isolates of Bacillus spp. This isolates were collected from 
Azorean soils of São Miguel Island. 79 bacterial isolates, previously tested for 
protease producers, were cultivate at 37˚C at 200rpm during 24 hrs in nutrient 
broth (0.5% Peptone, 0.3% beef extract and yeast extract, 0.5% NaCl, pH 7). 
After growth, bacteria was separated by centrifugation at 10000g for 10 min and 
supernatant was filtrated using 0.2 um membrane (Milipore) and then was 
concentrated using through tangential Concentration System (Minimate ™ TFF 
Capsule) with a 5K cut-off membrane. 
 
2. Proteolytic activity 
Bacillus isolates (79 isolates) were screened for their ability to 
hydrolyzed casein in 2% (w/v) agar plates containing 0.1% (w/v) of skin dry milk 
dissolved in 2% (w/v) agar for bacterial use, 2 ml of Tris HCI, pH 7.5, 25M buffer 
for buffering the medium. In the casein plate was made wells to pipette the 
bacterial supernatant. 
Inoculations were made of the 79 isolates in test tubes with 5 ml of 
nutrient broth and the supernatant was collected. 40 μL of supernatant from each 
isolate were pipetted into the wells in casein plate and was incubated for 24 hours 
at 37˚C. 
 
3. Fibrinolytic activity  
3.1. Agarose plate assay 
 Fibrinolytic protease activity was estimated according to the method 
described by Astrup and Mullertz, 1952. Using a fibrin plate containing a 56,25 
mg of fibrinogen from human plasma (Sigma) dissolved in 7,5ml of Tris-
HCl(25mM), pH 7.5 with 75mM NaCl, were added to this solution 7,5ml of 1.2% 
agarose and 100 μl of thrombin (Sigma) (100U/ml). The mixture was 
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homogenized and poured into the plate, reaching a thickness of 6-7mm, the plate 
was incubated for 30 min at 37˚C. Wells were made with 0.5 cm of radius.  
 Serial dilutions of enzyme were made (15 μg, 7.5 μg, 3.95 μg and 1.8 
μg in Tris-HCl pH7.5 solution) and serial dilutions of Urokinase (Sigma)(5 μg, 2.5 
μg, 1.25 μg, 0.6 μg)  20 μL of each were pipetted into the well, then the plate was 
incubated at 37˚C for 1, 2, 4, 6, 8, 12 hours. Plate scans were made for presence 
of digestion halos around each well where the sample was applied, the diameters 
of the digestion halos were measured. 
3.2. 96-well plate assay 
The method was developed for cost reasons to test the enzymatic 
activity on fibrin and plasminogen activation it was used a 96 well plate method. 
This method required less than 4% of human fibrin and human thrombin 
necessary compared with the previous plate method.  
In witch well of the 96-well plate was pipetted 50 μL of a fibrinogen 
solution (2mg of fibrinogen and 50 μl of Tris HCl pH 7.5 25mM with75mM NaCl) 
and 20 μl of diluted thrombin (0.02 μL of thrombin (100U/ml) and 19.98μl of 
distillated water). The plate was incubated for 30 min at 37 ˚C and then 20μg of 
samples were pipetted into witch well. Absorbance was read at 30 min intervals 
during 4 hours at a wavelength of 405nm, the decrease of absorbance meant the 
digestion of the fibrin clot. 
 
4. Plasminogen activation  
Plasminogen activation assay was performed in a 96-well plate assay 
and agarose plate assay as described above in Fibrinolytic activity (3) with minor 
modifications. 5 μg plasminogen was mixed with the samples, for testing the 
enzyme was added 15 μg of enzyme and 5 μg of plasminogen to an Eppendorf 
tube. Two controls were made one with 5 μg of plasminogen diluted in buffer Tris-
HCl (100mM), pH 7.5 and another with 5 μg of Urokinase diluted in buffer Tris-
HCl (100mM), pH 7.5.  
 Samples containing plasminogen were incubated at 37˚C for 5 min 
before being applied in the wells. The other samples containing just enzyme were 
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loaded directly into the wells, 30 μL of each mix of enzyme and plasminogen were 
pipetted into the respective wells of the fibrin plate and incubated at 37˚C. The 
digestion was followed by plate scan was made every hour during 6 hours in fibrin 
plate assay or absorbance readings at 405nm in 96-well plate assay. 
 
5. Fibrinogenolytic assay 
5.1 Evaluation of Fibrin clot formation 
To investigate the fibrinogenolytic activity of the enzyme was used the 
96 well plate method (3.2). 20 μg of sample was added to 50 μL of a fibrinogen 
solution (2mg of fibrinogen and 50 μL of Tris HCl pH 7.5 25mM with75mM NaCl) 
and a pre incubation of 10 min at 37˚C was made before adding 20 μL of thrombin 
solution (0.02 μL of thrombin (100U/ml) and 19,98 μl of distillated water). In 
positive control was used 20 μg of Urokinase and a negative control with Tris-HCl 
buffer were made to compare the fibrinogenolytic activity Absorbance was read 
at 15 min intervals during 5 hrs at a wavelength of 405nm. 
5.2 SDS-page analysis of fibrinogen chains digestion 
The fibrinogenolytic activity was also assayed according to Salazar et 
al. (2007), with some modifications. The method consists of pre-incubation of 
enzyme with fibrinogen to obtain a profile of degradation of fibrinogen chains (α, 
β and γ) through an SDS-page electrophoretic separation. For this 20μg of 
enzyme was added to 100 μL (0.08μg/μL) of fibrinogen from human plasma 
(Sigma) dissolved in Tris-HCl (25mM) pH 7.5 with 75mM NaCl and incubated at 
37˚C. Aliquots of 20 μL were taken from the mixture at different times (0, 10, 40 
and 1440 min). For a control was prepared a mix of 10 μg Urokinase (Sigma) and 
50 μL of fibrinogen from human plasma (Sigma) dissolved in Tris-HCl (25mM) pH 
7.5 with 75mM NaCl and incubated at 37˚C. Aliquots of 20 μL were taken from 
the mixture at different times (0, 20, and 1440 min). To the aliquots were added 
5μL of sample buffer containing β-mecaptoethanol. Samples were incubated for 
15 min at 95˚C and analyzed by a SDS-page. The separation of the proteins on 
the gel was visualized with Coomassie Blue staining. 
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6. Bacterial species groups identification 
In order to obtain the different restriction profiles, proceeded to the 
extraction of DNA and PCR amplification of the 16S rRNA gene. In order to obtain 
bacterial pellet to collect DNA, 5 μL of the bacterial culture was centrifuged at 
5000g for 5 min, the supernatant was discarded and the pellet was washed with 
500 μl of H2O milli-Q and stored at -80˚C, during 15 min. Then the samples were 
placed on 95˚C for 10 min to lysis the cell. Finally the cell suspension was 
centrifuged at 11000g for 5 min and the supernatant was stored at -80°C until 
needed. 
PCR reaction mixture was used 18.8 μl H2O milli-Q, 2.5 μL of buffer 
Tris-HCl, pH 8.3 with MgCl2, 0,5 μL of  dNTP, 10mM, 1μL of forward primer, 1 μL 
of reverse primer, 0,2μL Taq DNA polymerase and finally 0,5 μL of DNA.  
The PCR conditions for amplification of the 16S rRNA gene were: initial 
denaturation at 95˚C for three min followed by denaturation at 95 °C for 30 
seconds, annealing at 50˚C for 30 seconds, extension for 1 min at 72˚C by 35 
cycles and final extension at 5 min 72˚C. Finally the reaction was cooled at 4 °C. 
Then, the amplified fragments were analyzed using an electrophoretic run on 
1.2% agarose gel. A molecular weight marker (BIORON GmbH) of 100 Kb was 
used. 
After confirmation of 16S amplification the samples were digested with 
restriction enzyme AluI (AG'CT). For the reaction mix 5 μL of amplified product 
was joined with 5U of restriction enzyme in 20 μL total volume. Then incubated 
for 1 hr at 37ºC. Digested fragment was separated into 1.2% of agarose gel, a 
100 Kb molecular weight marker (BIORON GmbH) was used and the bands were 
stained with ethidium bromide. 
 
7. 16S Amplification and Sequencing  
A 16S amplification was made using a primer 8f 5’AGA GTT TGA TCC 
TGG CTC AG3’ and 1492r 5’ CCG TTA CCT TGT TAC GAC TT3’. For PCR 
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reaction mixture was used 18.8 μl H2O milli-Q, 2.5 μL of buffer Tris-HCl, pH 8.3 
with MgCl2, 0,5 μL of  dNTP, 10mM, 1μL of forward primer, 1 μL of reverse 
primer, 0,2μL Taq DNA polymerase and finally 0,5 μL of DNA. The conditions for 
amplification of the 16S gene were: initial denaturation at 95˚C for three min 
followed by denaturation at 95 °C for 30 seconds, annealing at 50˚C for 30 
seconds, extension for 1 min at 72˚C by 35 cycles and final extension at 5 min 
72˚C. Finally the reaction was cooled at 4 °C. 
The amplified DNA was purified with a PCR purification kit (Wizard SV 
Gel and Clean Up System, Promega) and then the sample was sent to 
sequencing DNA. 
 
8. SDS-page 
 For this electrophoretic analysis we used a vertical electrophoresis 
system Mini protean II Cell (Bio-Rad). There was a separation gel at 12% by the 
addition of 4 ml of acrylamide 30%, 2.5 ml buffer 0.375 M Tris-HCl, pH 8, and 0.1 
ml of 10% SDS, made up to volume with MilliQ water up to a total of 10 ml. 
 To polymerized the gel was added 75 μL of 10% APS and 30 μL 
TEMED. After its polymerization, butanol was removed and washed with MilliQ 
water. Once prepared the acrylamide gel concentration of 7% final concentration, 
was poured into the running gel and the comb is placed to create the wells during 
polymerization. The samples were dissolved in sample buffer with β-
mecaptoethanol and incubated at 95˚C for 15 min. The electrophoretic run 
occurred for 90 minutes at constant 24 Ampere 150 volts. The separation of the 
proteins on the gel was visualized with Coomassie Blue staining. 
 
 
9. Thrombolytic Activity 
 To determine the in vitro thrombolytic activity, was used a total blood 
clot provided by Centro Médico Dr Forjaz Sampaio, collected with a serum-Z-gel 
tubes. The blood clot was cut into small squares, with approximately 0.3 cm of 
length wise. Then the fragments were placed in 96-well-plate and washed with 
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0.1 M phosphate buffer solution pH 7 and 0.8% NaCl, to remove red blood cells 
detached from the clot. To a negative control was added 60 μL of 0.1M phosphate 
buffered saline. To check the thrombolytic activity of the enzyme a 60 μL mix was 
made with enzyme and 0.1M phosphate buffered saline.Then the plate was 
incubated for 37˚C for 4 hours. The microplate was scanned each 15 min to 
record the fragment size in each. 
 
10. Euglobulin lysis time 
 This assay was based on the method described by Smith et al, 2003. 
Consist in preparation of a euglobulin fraction from human blood plasma which is 
analyzed over time by reading absorbance at 405 nm. With tis assay we study 
the effect/action of the enzyme on the euglobulin lysis time. The euglobulin 
fraction was prepared by adding 400 μL of citrated human plasma to 3.6 ml of 
0.25% acetic acid (v/v), placed on ice for 30 min and centrifuged at 2000g at 20˚C 
for 15 min. 
 The supernatant was discarded and the tubes were inverted on paper 
swab for 3 min. The precipitate was resuspended by addition of 400 μL 0.1 M 
sodium borate solution, pH 9.0. lysis assay were prepared in a pre-warmed 37˚C 
96-well plate 150 μL of Euglobulin , 5 μL of thrombin solution, 5 μL of  0.1M CaCl2 
and 30 μL 0.1 M Tris-HCl. The enzymatic activity was tested replacing 0.1 M Tris-
HCl for the enzyme (10μg) and the enzyme was incubated for 15 min with 
euglobulin before adding thrombin and CaCl2. The control with Urokinase (Sigma) 
was made with 5μL of Urokinase (100/ml) dissolved in Tris-HCl 0.1M pH 7.5. The 
absorbance was measured kinetic spectrophotometer reader every 15 min during 
500 min. 
 
11. Hemolytic assay 
 For detection of hemolysis were used Columbia CNA Agar with 5% of 
Sheep Blood Medium from Biomerieux. Wells were made to the plate and 20μg 
of enzyme diluted in 0.1 M phosphate buffer solution pH 7 and 0.8% NaCl  were 
pipetted into each well. Scans were made during 1 hour intervals to see formation 
of a hemolytic disc surrounding the well. A positive control was made with 30μL 
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of H2O Mili-Q and a negative control was made with 40 μL of PBS buffer with 
0.8% of NaCl. The CAN plate was incubated for 6 hrs at 37˚C. 
 
12. Purification of the Fibrinolytic Enzyme 
 All chromatograhies were performed on a AKTA-FPLC system at 7˚C. 
The enzyme fractionation was done using 4 liters of 18 hrs bacterial culture and 
the supernatant was then separated by centrifugation at 8000g, 10min, filtrated 
with a 0.2 um membrane and concentrated with tangential Millipore 
Concentration System (Minimate ™ TFF Capsule) with a 5K membrane. 
 Bacterial supernatant was used to fractionate in successive 
chromatographies. The first one was an anionic exchange chromatography at pH 
8.8, using a Capto Q column. The column was equilibrated with 50mM of Tris-
HCl pH8.8 (Buffer A)  protein was eluted with 5 steps of 0%, 15%, 30% 60% and 
100% 50mM  Tris-HCl, pH 8.8 with 1M of NaCl (Buffer B). Eluted proteins 
automatically collected using a chromatography system collector. The proteolytic 
activity was determinate with a 96-well-plate fibrin assay.  
Active fractions were pooled, concentrated and applied in a HitrapQ 
column equilibrated with 50mM Tris-HCl, pH 8.8 (Buffer A). Proteins were eluted 
with 50 mM Tris-HCl, pH 8.8 with 1M NaCl (Buffer B) in a gradient (0%; 5%; 5% 
to 30%; 30% to 50% and 50% to 100%). After testing each fraction of the Hitrap 
Q the active fraction was applied in an anionic exchanger column Mono Q, 
equilibrated with 50mM Tris-HCl, pH 8.8. The protein was eluted by Tris-HCl 
pH8.8 with 1M of NaCl, The different fraction were tested in a 96-well plate and 
the fraction with the best fibrin digestion was used.  
 
13. Zymogram of Purified Enzyme 
 The enzyme fraction with fibrinolytic activity detected was separated 
on SDS-PAGE supplemented with gelatin. The zymogram was performed on gel 
with 12% acrylamide / bisacrylamide in 1.5 M Tris-HCl buffer solution (pH 8.8) 
copolymerized with gelatin to 0.10%. Sample (20 μL) were loaded on the gel with 
15 μL of the purified enzyme, and 5 μL sample buffer. After the electrophoretic 
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run on a Mini Protean Cell II (Bio-Rad) system, the gel was washed 2 times for 
30 minutes with 2.5% Triton X-100 and removed with 3 washes in distilled water 
for 10 minutes. 
 After that the gel was incubated for 3 hrs in buffer 50 mM Tris-HCl, pH 
7.5, at 37˚C.The areas in which it occurred proteolytic activity were detected by 
Coomassie blue staining.. 
 
14. SDS- page of purified fraction 
 After the chromatography purification, the soluble purified protein 
concentration was determinate using a NanoDrop spectrophotometer 
(Thermoscientific). The purified protein was precipitated with acetone and 
tricloroacetic acid (TCA). 
The purified fraction was added 5μL of sample buffer with β-mecaptoethanol, the 
mix of Sample and Buffer was incubated at 95˚C for 15 min. The electrophoretic 
run occurred for 90 minutes at a constant 24 Ampere 150 volts. The separation 
of the proteins on the gel was visualized after a Coomassie Blue staining. 
 
15. Mass Spectrometric analysis of the Enzyme (Ms/Ms)  
 After separation of the protein by SDS-PAGE gel, the band 
corresponding to the pure fraction was cut from the gel and placed in Eppendorf 
tubes and covered with milli-Q water. Samples were sent to the Group of Mass 
Spectrometry at the Institute of Chemical and Biological Technology (ITQB, 
Oeiras) for analysis. 
The monoisotopic mass of the analyzed proteins were obtained using a MALDI-
TOF-MS model Voyager-DE STR (Applied Biosystems). The external calibration 
masses was performed using a mixture of peptides patterns PepMix1 (Laserbio 
Labs). The masses obtained were used to search the NCBI database 
(www.ncbi.nlm.nih.gov) using the public version of the Mascot software 
(www.matrixscience.com). 
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16. Biochemical Characterization of the Enzyme 
 
16.1 Effect of pH and Temperature 
 To determinate the optimal pH were used 0.1M of Tris-HCl buffer at 
pH 6.5, 7.5 and 8.5. For each pH range was added to an eppendorf, 20 μL of 
buffer, 30 μL of enzyme fraction, and 50 μl of 2% azocasein. In a negative control 
the sample was replaced by buffer. The effect of temperature on the enzymatic 
activity was also determined by azocasein. The assay was performed at different 
temperatures, 28°C, 37°C and 48°C. For each temperature an Eppendorf 
prepared with 20 μL of buffer, 30 μL of enzyme fraction, and 50 μl of 2% 
azocasein. A negative control for each temperature, where only buffer was added 
and the solution was made substrate. 
  
16.2 Effect of Ions and Solvents and on enzymatic activity 
 To determine the effect of various solvents and ion on the enzymatic 
activity was carried a standard azocasein test with 5 μL 0.1M of ions, 30 μL of 
enzyme fraction, 15 μL of buffer solution and 50 μL  of 2% azocasein (w/v). In 
this case a positive control was made without sample and solvents. Was made a 
negative control containing 0.1M Tris-HCl buffer. Ions used were the HgCl2, 
MgCl2, CuSO4, NiCl2, MnCl2, KCl, NaCl, and CaCl2. To check for enzyme stability 
with solvents were used Urea, SDS, β-Mercaptoethanol, Chaps, Triton, Tween 
and DTT. 
 
16.3 Substrate specificity  
 Proteolytic activity was measured using specific chromogenic 
substrates. MetSuc-Ala-Ala-Pro-Met-pNa, Suc-Ala-Ala-Pro-Phe-pNa and Suc-
Gli-Gli-Phe-pNa to analyses chymotrypsin- like activity; Bz-Phe-Val-Arg-pNa and 
Bz-Pro-Phe-Arg-pNa to analyse thrombin- like activity; Bz-Gli-Gli-Arg-pNa for 
Urokinase- like activity; Z-D-Arg-Gli-Arg-pNa for factor Xa like activity; and the D-
Ile-Pro-Arg-pNa for plasminogen activator like activity. Enzyme was mixed with 
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witch chromogenic substrato dissolved in 0.5 M Tris-HCl pH 7.5. The formation 
of p-nitroaniline was monitored at 405 nm by BioRad reader. 
 
 
16.4 Effect of Inhibitors on enzymatic activity 
 The effect of various protease inhibitors on enzyme activity was tested 
with specific substrate. Was added to 5μL of specific substrate, 15 μL of buffer, 
15 μL of enzyme fraction, and 5 μL of inhibitor. The mixture was pre-incubated at 
room temperature for 5 min and then was added to 5 μL of Specific substrate. 
The inhibitors used were benzamidine (serine protease inhibitor), STI (soybean 
trypsin inhibitor), E64, phenanthroline (metallopeptidases inhibator), PMSF (srine 
protease inhibator), phosphoramidon, cysteine, EDTA (mataloprotease 
inhibator), leupeptin, chymostatin (Chymotrypsin-like inhibator), TPCK and 
antithrombin. A control was made without inhibitor. The activity was monitored at 
405nm after 1 hour. 
 
  
17. In Vitro anticoagulation assay 
  This test was used to evaluate the Activated Partial Thromboplastin 
(APPT) and Thrombin time (TT) values. This test was carried out in three different 
situations automatically using a coagulometer with approved methodology for 
coagulation tests in laboratory. The test was performed at Centro Médico Forjaz 
Sampaio, in which the movement of magnetic beads allows to calculate the 
plasma clotting time. It was very important to detect quantitative and qualitative 
coagulation abnormalities induced by enzyme in plasma constituents. 
 The assay was performed according manufacturer’s instruction and 
laboratory standards. Were used commercial reagents Cefalin and CaCl2 to 
induced the human plasma clot. The coagulometer was preheated for 3 min, in 
the first situation was added to 100 μL of plasma to a cuvette with a metal bead 
and the coagulation was induced by 10μL of 0.2M CaCl2, when the metal beads 
stooped the coagulation time was measured in seconds. To compare the time of 
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clot formation with a standard situation was added 80 μL of plasma and 20 μL of 
enzyme solution (5μg/μL) to the cuvette with the magnetic bead. Finally added 
50 μl of 0.02 M calcium chloride to the mixture in the cuvette and the coagulation 
time was measured through the magnetic bead movement. After the coagulation 
the cuvette were incubated at 37˚C and scans were made during 3 hours. 
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III Results 
 
1. Proteolytic activity of the Bacterial Isolates 
The purpose of this research was determining bacterial isolates 
producing proteases in larger amount. From the 79 isolates tested were chosen 
the isolates with the largest digestion halo (Figure 1. and Annex Figure 2). From 
this result were selected 27 isolates with higher proteolytic activity (Figure 1): 
S115C (1.62 cm), S122C (1,38 cm), S127E (1.17cm), S144B (1.09 cm), S62A 
(1.06 cm), S25E (1.05 cm), S101C (1.03 cm), S25B (1.01 cm), S150C (1 cm), 
S157E (1 cm), S99A (0.96 cm), S99D (0.88 cm), S61B (0.78 cm), S140E (0.75 
cm), S52D (0.75 cm), S109A (0.75cm), S117E (0.71 cm) S97B (0.7 cm), S125B 
(0.68 cm), S26A (0.65 cm), S88A (0.62 cm), S144D (0.6 cm), S62D (0.59cm), 
S178B (0.58 cm), S54D (0.57cm), S137B (0.5 cm), S148A (0.5 cm) 
  
Figure 1: Agar casein plate assay. Casein digestion halos in centimeters (cm) from a 
total of 79 bacterial isolate. The plates were incubated 24hrs at 37 ºC. 
 
2. Screening of fibrinolytic activity 
 The fibrinolytic activity was detected by plate method with the 
appearance of digestion around halos. In total 14 showed fibrinolytic activity but 
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we selected the 11 with more activity. Therefore the radius of halos in cm was 
measured in each sample and compared with Urokinase as a positive control. 
Were select 14 isolates with higher fibrinolytic activity (≥1.5 cm) with: S122C (2.28 
cm), S150C (2.31), S157E (2.24), S178C (1.9 cm), S115C (1.5 cm), S62A (2.12 
cm), S99D (2.54 cm), S101C (1.91 cm), S88A (2.33 cm), S26A (2.28 cm) and 
S97B (2.01 cm) (Figure 2, Annex: Figure 2). 
 
Figure 2: Fibrinolytic activity of the 27 samples. Fibrin digestion halos in centimeters 
(cm) in agarose fibrin plate. After incubation for 16 hrs at 37˚C. 
 
3. Thrombolytic Activity in vitro 
 The enzymes that present higher fibrinolytic activity were tested for 
thrombolytic activity. The clot digestion was measured by reduction of clot size 
ant the release of hematocytes in the well (the increment of color in the well). 
It is observed that in first hour of incubation the samples S122C, S157E, 
S97B and S150C present high digestion. After 3 hours we can see that S115C, 
is starting to digest the clot by the shape of the clot and the color of the well 
(Figure 3). Looking at the rest of the isolate we can not see a significant  diference 
in the blood clots shape. 
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Figure 3: 96-well Microplate with enzymatic digestion of blood clots throughout the 
incubation period at 37˚C. 
 
4. Genetic identification of isolates based on PCR-ARDRA profile 
In order to identify the groups of bacillus the 16S rRNA of all bacterial 
strains used in this work was amplified and a restriction enzyme profile was 
obtained (Wu et al., 2006). 
It was possible to amplify the 16S gene from all isolates yielding a band 
of 1500 bp, which corresponds to the size of the expected fragment. Were 
detected 3 different restriction profiles (Figure 4.A) one presenting fragments of 
600 bp, 220 bp and 180 bp, another one with 550 bp, 220 bp and 180 bp 
fragments and another group with fragments of 450 bp, 280 bp and 230 bp. 
According to Wu et al., 2006 the first group correspond to Bacillus group 
I witch include 3 fragments of 600 bp, 220 bp and 180 bp. Bacillus Group II has 
a similar profile to group I, except the largest fragment is 550 bp. The restriction 
profile of Group VII contain a fragment of 450 bp, a fragment with 280 bp and a 
fragment with 230 bp (Figure 4.B) 
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The ARDRA profile (Figure 4, B) genetic Bacillus group I, corresponds 
to the species of B. cereus, B. anthracis or B. thuringiensis, in Bacillus group II 
we can find B. mycoides and B. weihenstephanesis. The genetic profile of group 
VII corresponds to species of bacteria like B. subtilis, B. pumilus, B. 
amyloliquefaciens or B. atrophaeus. 
 
 
Figure 4: Electrophoresis gel with different restriction profile ARDRA by AluI. A) Pattern 
of different isolates digested with AluI. B)  Three different 16S rRNA restriction profiles 
by AluI. 
 
Table 1: The three different genetics groups of 11 isolate 
Group Isolate Bacillus sp. 
I S178C, S99D, S88A, S97B B. cereus and B. 
anthracis 
II S115C, S101C, S62C, S26A B. mycoides and B 
weihenstephanesis 
VII S157E, S122C, S150C B. subtilis, B. pumilus, 
B. atrophaeu and 
B.amyloliquefaciens 
. 
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5. Optimal Temperature and pH 
 Of the three Bacillus groups studied so far we want to select one 
isolated from each group. The selection of these isolates had as parameters the 
fibrinolytic activity and its activity in the physiological conditions of the human 
organism, pH 7.5 and temperature 37˚C (Figure 6). pH and temperature assays 
were very important to help choose the right isolate with fibrinolytic activity in 
human physiological conditions. The optimal pH for the most isolates was pH 7.5 
(Figure 5). 
Figure 5: Effect of pH on the enzymatic activity with generalist substrate azocasein. 
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Figure 6: Efect of temperature on the enzymatic activity with generalist substrate azocasein. 
 The bacterial isolates with a better activity at a pH7.5 were S122C, 
S150C, S157E, S115C, S62A S101C, S88A and S97B (Figure 5). In terms of 
temperature, the isolates with a better activity at 37˚C were S122C, S157E, 
S178C, S115C, S62A S101C, S88A and S97B. S99D AND S101C had an 
optimal temperature 28˚C (Figure 6).  
 
6. Hemolytic activity 
 For the hemolytic activity (Figure 7, Annex: Figure 3), was used a 
Columbia CNA Agar plate with Sheep Blood Medium and the  activity was 
detected by a presence of a clear halo around the wells. The positive control used 
was MilliQ H2O, which causes lysis of hemocytes through osmotic movement of 
water into the interior of cells, the diameter was about 4 cm. As for the most of 
the samples the hemolytic halo was between 0.5 cm and 2.1 cm. 
  It was found that two enzymes, S115C and S101C had small smudge, 
indicating that this two enzymes does not cause red blood cells lysis. Curiously 
this 2 enzymes correspond to the same bacillus group (B. Mycoides).   Moreover 
previous tests showed that S115C and S101C had fibrinolytic activity, becoming 
the best choices for the further investigation.  
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Figure 7: Hemolytic assay: hemolytic halos in centimeter (cm) after a incubation of 4 
hour at 37˚C. the positive control (C+) was distillated water. 
 
7. Influence of S115C and S101C on clotting time and plasma clot lysis 
The assay of the activated partial thromboplastin time (aPTT) and 
Prothrombin time (PT) allows to investigate the enzyme effect on the clotting time 
and the action on the plasma clot. No significance differences in PT were showed 
between control and respective cuvettes containing enzyme S115C and S101C. 
In aPTT test the objective was to evaluate the effect of enzyme on the 
coagulation time, and both enzymes were applied at the start of the test, acting 
during the process of coagulation. It was found that the cuvettes containing 
enzyme S101C presented an accentuated increase in activated partial 
thromboplastin time, 55 seconds, S101C caused alteration in the intrinsic and 
common pathway of coagulation. Thus S115C didn’t show a significant variation 
clotting time was 35 seconds. 
In the PT assay both enzymes didn’t show significates differences, 
prothrombin time of S115C and S101C were, respectively, 13 seconds and 13,2 
seconds didn’t disturbed the extrinsic pathway of coagulation. 
S115C values are inside the reference values for healty humans. The 
reference range of the aPTT is 30-40 seconds and the reference range of the PT 
is 11-14 seconds. 
The cuvettes with the clot and the enzyme were incubated at different 
times at 37˚C, the plasma clots showed some changes in their shape and size 
during the incubation period, reaching smaller after 3 hours of incubation. The 
biggest reduction on the plasma clots was seen in the cuvette with S115C (Figure 
8). 
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Figure 8: Clotting time and plasma clot lysis during the incubation period (10min, 1hr, 
2hrs and 3 hrs). S115C and S101C were applied after clotting enzyme; CT-clotting time. 
(→) plasmatic clot digestion 
 
8. Plasminogen activation of S101C and S115C 
To compare the plasminogen activation we created two different 
situations. the first one the well  was supplemented with plasminogen the other 
one the well didn’t have plasminogen, it was found that the well with plasminogen 
the enzyme digestion was enhance with the presence of S101C while S115C 
didn’t show significant difference as expected. This result indicates that S101C is 
a great plasminogen activator, increasing meaningfully the fibrinolytic activity 
(Figure 9). Fibrinolytic enzyme activity of S101C and S115C was detected by a 
fibrin 96 well plate method. S115C showed more lytic activity, thus S101C is a 
great plasminogen activator. 
 
 
At this point of the work we selected enzyme S115C for its fibrinolytic, 
hemolytic and thrombolytic activity this enzyme didn’t altered the normal and 
healthy coagulation pathway as confirmed with aPTT, PT test and euglobulin lysis 
time. S115C was named BmK. 
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Figure 9: Plasminogen activator and fibrinolytic activity of S101C and S115C after 2 hrs 
incubation at 37˚C. Control (c) just with plasminogen. 
 
9. In vitro Thrombolytic Activity of BmK 
 We tested BmK’s ability to degrade the clot through the examination 
of clot fragments size, a photo was taken to the clots in 30min intervals (Figure 
10). BmK digest the whole blood clot in 90 min while the negative control didn’t 
digest the blood clot as espected. 
 
Figure 10: 96-well Microplate with enzymatic digestion of blood clots throughout the 
incubation period. BmK (30μg); C - negative control with 0.1 M phosphate buffered saline 
solution. 
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10. Enzyme Purification 
During the fractionation process, it was found that the enzyme of interest 
has an alkaline isoelectric point, pH was above 8. In the first chromatography, 
CaptoQ. The fractions were collected and concentrated in peaks, each peak was 
tested with a 96-well plate method with fibrin.  Was identified one peak with a 
higher enzymatic activity in exclusion, this peak was named CQP1 and the 
second peak eluted also showed activity. 
 
Figure 11: Anion-exchange chromatography with Capto Q column. mAU - Absorbance; 
% B- salt gradient; % activity of Fibrinolytic activity. 
 
The peak with higher activity obtained in capto Q (CQP1) was injected in 
a anionic exchange chromatography using a HitrapQ column (Figure 12). In this 
chromatography separation was obtained two clear peaks of protein. The first 
peak (HQP1) eluted in the exclusion showed low activity, in the last peak (HQP2) 
showed 65% of fibrinolytic activity (Figure 12). The fraction corresponding to the 
peak containing the protein of interest, at pH 8.8, is positively charged and was 
retained in the stationary phase with a moderate ionic strength and left the column 
when the eluent gradient increased. 
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Figure 12: Anion-exchange chromatography HitrapQ column. mAU - Absorbance; % B- 
salt gradient; % activity of Fibrinolytic activity. 
  
The HQP2 from HitrapQ was injected in a MonoQ anionic exchange 
column. After testing all the fractions was selected the #16 and #17 that belong 
to the last peak (MQP6). #16 and #17 had, respectively 58% and 42% of 
fibrinolytic activity (Figure 13). #16 and #17 were pooled and used for SDS-page 
and Zymogram. 
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Figure 13: Anion-exchange chromatograpgy MonoQ column. mAU - Absorbance; % B- 
salt gradient; % activity of Fibrinolytic activity. 
 
Table 2: Purification table of BmK 
Sample mL mg/mL [mg] Total act. (U) 
Specific act. 
(U/mg) 
Purification 
Factor 
Bmk 1,5 57,6 83,4 483 6  
CQP1 0,8 6,03 4,824 201 42 7 
HQP2 0,7 0,585 0,409 258 631 109 
MQP6 1 0,08 0,08 279 3488 698 
 
 
11. Zymogram and SDS-page of Purified Enzyme. 
The zymogram of chromatography fraction of BmK enzyme revel a 
digestion band higher than 135 kDa and another band at 75kDa. SDS-page of 
fraction revel 3 bands one at 37 kDa, one at 75 kDa and another higher than 
180kDa (Figure 14). The band with 75kDa and the band with 200 kDa in the SDS-
page were the ones with activity according to the zymogram (Figure 14.A) these 
two bands were cut and sent to Protein Mass Spectrometry Analysis (Ms/Ms). 
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Figure 14: A Zymography of the chromatography BmK Enzyme (1) B SDS-page of the 
chromatography fraction. MW- molecular weight; 1-Chromatography fraction of BmK 
Enzyme.  
 
12. Euglobulin lysis time S115C. 
 The influence of BmK enzyme on the coagulation time or the lysis time. 
We had the same test running in different situations. The first one as positive 
control the test was performed under normal conditions without the addition of 
enzyme, the second situation was applied the enzyme S115C fractionated and in 
the third situation Urokinase was added to the clot. To see if the enzyme Bmk 
interfere with intrinsic coagulation pathway was made a pre incubation of 10 min 
with enzyme and euglobulin before adding thrombin e calcium.  
In the first situation we can see that in 350 minutes the Euglobulin clot 
started to decrease, as expected according to the a normal references for 
euglobulin clot lysis time, at 500 minutes the clot disappeared completely.
 In the situation designated by BmK  the fractionate S115C enzyme 
was present and the absorbance increase, which is a sign of clot formation, 
however after 15 min started digesting slowly the clot and at 255 min the digestion 
of the clot was complete, which indicates the euglobulin clot lysis. These results 
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confirm once again the fibrinolytic activity of this enzyme, which acts upon the 
fibrin fibers reducing the time of the euglobulin clot lysis (Figure 15).  
 
Figure 15: The euglobulin lysis time in different situations. Normal situation (Positive 
control); BmK enzyme fraction application at start of test (BmK); Urokinase control (UK). 
Incubation during 550 minutes at 37˚C. 
 In the situation were Urokinase UK was added it was found that there 
wasn’t a big increase in absorbance, although in 15 min the absorbance was at 
0.1 nm, this fact indicates that the clot was already dissolved. 
 
13. Biochemical characterization of S115C 
13.1 Effect of Ions and Solvents on enzyme activity 
 
 In the assay azocasein to different ions (Figure 16), it was found that 
MnCl2 , NaCl and CaCl2 ions contribute to the increase of enzyme activity, 
however the optimal enzyme cofactors is Manganese, since this reaches an 
activity increase of around 95%, while that Calcium and Sodium contributes only 
a slight increase in activity. All other ions cause an inhibition of the activity, NiCl2 
inhibits the enzymatic activity in 37%, and CuSO4 inhibit the activity of around 
31%, MgCl and KCl inhibits less than 15%, HgCl2 does not interfere with the 
normal enzyme activity. 
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Figure 16: Effect of ions in enzyme activity with the substrate general azocasein. 
Incubation for 3 hour at 37˚C. 
 
With regard to solvents, SDS was the only solvent that didn’t interfere 
with the activity, however β-mercaptoethanol inhibits completely the enzyme 
activity. Urea, Chaps Triton and DTT showed a strong inhibitory effect (>60%) 
(Figure 17). SDS is an ionic detergent the enzyme is not stable in presence of 
nonionic solvents and denaturant agents.  
 
Figure 17: Effect of solvents in enzyme activity with substrate general azocasein. 
Incubation for 3 hrs at 37˚C. 
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13.2 Substrate specificity  
Different synthetic chromogenic substrates were used to screen the 
enzyme specificity. The enzyme has shown greater specificity for the Suc-Ala-
Ala-Pro- Phe-pNA substrate whose absorbance value increase (Figure 18). The 
substrate is specific for chymotrypsin, confirming again that enzyme in question 
belongs to the family of serine proteases of the chymotrypsin. 
 
Figure 18: Enzyme activity with different specific substrates. Incubation for 1 hr at 37˚C. 
 
13.3 Effect of Inhibitors in enzyme activity 
Benzamidine, STI, Chymostatin and TPCK were the inhibitors with 
highest percentage of inhibition of the enzyme BmK 100%, 100%, 93% and 82%, 
respectively (Figure 19). Benzamidine and STI are inhibitors of serine proteases 
and trypsin-like enzymes, TPCK is a serine protease inhibitor. The Chymostatin 
is a strong inhibitor of many proteases, particularly chymotrypsin, serine 
proteases of the chymotrypsin-like. Since the inhibitor is PMSF large spectrum of 
action on serine proteases. The metalloprotease inhibitor EDTA showed a 
inhibitory effect on the enzyme (70%), serine protease inhibitors like PMSF also 
affect the activity (68%) (Figure 19). The percentage of inhibition is low, below 
20%, with antitrombin, since antithrombin is used as a inhibitor of thrombin, 
plasmin, trypsin and factors IXa, Xa and XIa clotting cascade.  
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Figure 19: Effect of Inhibitors in enzyme activity with substrate general azocasein. 
Incubation for 3 hrs at 37˚C. 
 
14. Fibrinolytic activity of BmK 
 BmK showed a transparent area surrounding the well on the fibrin 
plate, this area is the lytic area where the fibrin had been degraded into soluble 
peptides (Figure 20). Was also observed that BmK digest fibrin at a dose 
dependent ratio and comparing with UK digest fibrin less than 3 times. 
  
.  
Figure 20: BmK enzyme fraction in different concentrations (15μg, 7.5μg, 3.75μg, 
1.8μg). Urokinase in different concentrations (5μg, 2.5μg, 1.25μg, 0.62μg). 
Incubation for 4hrs at 37˚C. 
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 To calculate the activity constant according to Wang et al., 2012, 
relates to the halo radius of enzymatic digestion with the diffusion time in the fibrin 
plate (R/√t) for both enzymes, allowing to estimate the activity units of the enzyme 
of interest from commercial Urokinase of known activity (Table 3). The activity 
constant obtained for the BmK and the enzyme Urokinase, was 2.77 and 3.31 
respectively. The constant value of BmK was 1.25 less then UK value.  
 
Table 3: Calculation of the activity constant for different incubation times and 
estimating the activity units per ug through known Urokinase 
Time (hrs) BmK  Uk 
1 2,81 3,53 
2 2,31 2,89 
3 2,73 3,24 
4 2,81 3,38 
Mean 2,77 3,31 
 . 
 
 To investigate the fibrin digestion pattern we made a SDS-page using 
fibrin that was already digest by 15 μg and 5 μg of BmK. A positive control was 
made using fibrin digest by 5 μg of Urokinase. This pattern correspond to a 
incubation of 3 hours. Fibrin has the same structure than fibrinogen the only 
difference is that fibrin is insoluble. We can see that with Urokinase fibrin were 
degraded in various bands resulting one high molecular weight band at 
approximately 40 kDa and various other ranging between 15 and 35 kDa. BmK35 
and BmK5 showed a similar digestion pattern, the difference is that with a 
concentration of 35μg the bands are darker suggesting an enhanced digestion of 
fibrin (Figure 21). 
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Figure 21: Fibrinolytic SDS-page. M (Molecular Weight) Mix of 5 μg of Urokinase and 
fibrin (UK5); Mix 35μg of BmK enzyme fraction and fibrin (BmK35). Mix 5μg of BmK 
enzyme fraction and fibrin (BmK5). 
 
 
 
 
15. Plasminogen activation of BmK 
The fibrinolytic activity on the BmK enzyme was compared in the 
presence and absence of plasminogen. In the presence of plasminogen the lytic 
area of the Bacillus enzyme was not enhanced (Figure 22). As expected 
Urokinase that was used as a positive control, its halo degradation was enhance 
with plasminogen as compared with the well without plasminogen, indication 
plasminogen activation.  
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Figure 22: Plasminogen activation assay. Urokinase (UK5μg); BmK enzyme fraction 
(BmK15μg); Plasminogen (5μg). Mix Urokinase and plasminogen (Uk5μg+5μg plasminogen; 
Mix Bmk fraction with plasminogen (Bmk15μg+5μgpalsminigen). 
 
16. Fibrinogenolytic activity of BmK 
To investigate the interaction between Bmk and fibrinogen was made a 
separation by SDS-PAGE gel which was charged with a mix of fibrinogen and 
BmK and this mixture was incubated at different times. A control was made 
mixing fibrinogen with Urokinase and was incubated in different times (Figure 23). 
 Fibrinogen consists of α chain of 64 kDa, 57 kDa β chain and the γ 
chains having 48 kDa molecular weight. 
 As can be seen, soon after mixing the enzyme with the fibrinogen the 
degradation of fibrinogen didn’t happened. We found that the pattern of 
fibrinogen, α, β and γ chains, is the same even with 24 hours of incubation. This 
shows that Bmk has a high specify for fibrin and not for fibrinogen. With the control 
with Urokinase (UK) we can see at 0 min an instant degradation of α, β and γ 
chains. 
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Figure 23: Fibrinogenolytic SDS-PAGE. Fg-fibrinogen. And mix of enzyme and fibrinogen 
with different incubation periods. MW-Molecular Weight; 1-Fibrinogen; 2 Mix fibrinogen and 
enzyme 0 min; 3- Mix fibrinogen and enzyme 10 min; 4- Mix fibrinogen and enzyme 40 min; 
5- Mix fibrinogen and enzyme 24hrs; 6- Mix fibrinogen and Urokinase 0 min; 7- Mix fibrinogen 
and Urokinase; 40 minutes; 8- Mix fibrinogen and Urikinase 24hrs. 
 
 The UK degradation profile was completely set after a 20 min 
incubation, disappearing the other two α and β chains of fibrinogen. The 
degradation profile has diverse bands resulting from the degradation of various 
fibrinogen chains. One molecular band that after 24 hour still intact was a 48kDa 
band (γ). 
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IV Discussion 
 
 From the 79 isolates with proteolytic activity 27 were selected with 
better activity in physiological conditions, pH 7.5 and 37˚C. These 27 bacterial 
isolates were tested for fibrin activity and 11 show fibrinolytic activity. From this 
11 only 5 bacterial isolates presented thrombolytic activity. 
After obtained the ARDRA restriction profiles (amplified ribosomal DNA 
restriction analysis) of 16S rRNA with the enzyme AluI to 11 bacterial isolates. It 
was possible to distinguish three different genetic groups based on the restriction 
band profile obtained. The isolates S178C, S99D, S88A and S97B belong to 
group I, with a characteristic profile of Bacillus cereus species belonging to the 
group containing the species B. anthraci, B. thuringiensis and B. cereus. As for 
Group II which corresponds to the species B. mycoides and B. weihenstephanesi 
belong isolated S115C, S101C, S62C and S26A. For the genetic group VII belong 
to isolates S122C, S150C and S157E witch correspond to the species B. subtilis, 
B. pumilus, B. and B. amyloliquefaciens. Several strains of the species B. subtilis 
and B. amyloliquefaciens are described in other studies as producers of 
fibrinolytic enzymes. 
 
 Previous studies shown that fibrin is a very difficult to digest, only 6% 
of the isolates studied in this work were capable of digestion a blood clot. It is 
noted that the three dimensional conformation and the disposition of the fibers of 
fibrin into a blood clot is different and more complex than the configuration shown 
an agarose plate comprising only insoluble fibrin. At the end of the clotting 
cascade which culminates in the activation of thrombin which converts fibrinogen 
to insoluble fibrin is the activation of other important factors. From the three 
fibrinogen chains (α, γ, β), only the α and γ chains, undergo cross-linking by factor 
XIIIa. During clot formation in the early stages of polymerization, cross-linking 
occurs within the protofibrils, between the various chains, resulting in dimers γ 
training and the multiple connections between α chains, resulting in formation of 
α polymers (Collet et al., 2005; Chen and Doolittle, 1969; McKee et al., 1970). 
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 From the fibrinolytic enzymes selected enzymes only 2 didn’t 
presented hemolytic activity. In previous studies physiological abnormal activities 
has been have been identified, some of them include immunomodulatory and 
hypocholesterolemic actions, and antitumor, anti-inflammatory, anti-allergic, 
anticoagulation, and antithrombin activity as well as fibrinogenolysis stimulation 
(Lu et al., 2010; Wang et al., 1995). After hemolytic assay were chosen two 
Bacillus mycoides, S115C and S101C. This enzymes that curiously belongs to 
the same Bacillus group specie, didn’t cause red bool cells lysis proving to be 
capable of digest blood clots without interfere with blood function.  
A thrombolytic test was made to investigate the ability of S115C and 
S101C to degrade blood clots with all its constituents present and the tests is 
used to evaluate the influence of the enzyme in clot digestion. After analyzing the 
results obtained in the test, it was found that S115C enzyme was able to 
completely degrade a blood clot after 90 minutes, contrasting with S101C which 
didn’t digest the clot, blood clot stayed intact. 
 The analysis of the results obtained in the plasminogen activation 
assay, it is concluded that S115C enzyme is capable of degrading the fibrin 
directly without activation of plasminogen, otherwise S101C like Urokinase is a 
plasminogen activator (Veljkovic, DK. et al. 2009). S115C enzyme which digest 
directly the fibrin fibers similar to Nattokinase (Kotb, 2013). 
 
 Activated partial thromboplastin time (aPTT) allows to determinate the 
blood plasma coagulation time. With this assay we evaluate the effect of S115C 
and S101C on clotting time and subsequently their action on the plasma clot. 
After analyzing the results, it was found that the S115C enzyme did not affect the 
normal clotting time, and later caused a slight deterioration of plasma clot. With 
these results it was concluded that S115C enzyme does not interfere with the 
coagulation process unlike S101C that elongated significantly the normal clotting 
time. 
 
In this work we had always in consideration finding a enzyme that didn’t 
interfere with the human biological function. 
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S115C was chosen not just for its high specify for fibrin digestion but 
also its no specify for fibrinogen. The fibrinogenolytic activity of the S115C 
enzyme (Bmk) was determined, and the purpose was to investigate whether the 
enzyme is capable of degrading the fibrinogen chains α, β and γ (McKee et al, 
1970). A positive control with Urokinase was made to compare the digestion 
patterns. 
The enzyme BmK didn’t degraded fibrinogen α, β and γ chains, even 
after a 24 hour incubation. So BmK enzyme is able to digest easily fibrin but don’t 
digest fibrinogen which is in its soluble state, however its insoluble fibrin fibers 
degradation capacity is high. With the positive control UK the digestion of α and 
β chains was instant, in 0 min we have a digestion pattern. 
The fact that BmK didn’t showed fibrinogenolytic activity is beneficial to 
future enzyme applications, because the intravenous application of the enzyme 
will not interfere with fibrinogen concentration in the blood. Patients don’t have 
the risk of bleeding problems (Karlsson, et al., 2002). 
It was also possible to evaluate the effect of the enzyme in the 
Euglobulin Lysis Time. In this case, what is being assessed is the time that 
elapses from the clot formed until lysis. The enzyme was applied before 
euglobulin clot induction. In this situation Bmk was mixed with euglobulin and a 
pre incubation was made for 5 min, next was added calcium and thrombin, it was 
found that the plasma clot actually occur. It was concluded that the enzyme hasn’t 
degraded fibrin as it was being formed by thrombin and calcium and the 
euglobulin clot formed. Euglobulin clot started to disappeared around 380 min 
thus euglobulin clot with BmK started to been digest at 30 min 
It is noted that in Euglobulin Lysis Time method, unlike APTT method, 
the amount of involved fibrin or is produced is in very minor amounts, allowing for 
greater sensitivity to the assay as the proportion of enzyme and substrate are 
more balanced. These results confirm once again the fibrinolytic activity of this 
enzyme, which acts reducing the time of the euglobulin clot lysis. 
 For the characterization of S115C enzyme (BmK) were studied the 
effect of the various ions / solvents and inhibitors on enzyme activity and was 
determinate the specific substrates of the enzyme. The optimum operating 
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temperature of BmK enzyme is approximately 37°C which is the physiological 
temperature of the human body. The enzyme exhibits maximum activity in neutral 
pH, with an optimum pH of 7.5, very close to the pH of human blood, indicating 
that this enzyme will offered a good activity if administered by intravenous 
injection. For the purposes of the ions on the enzyme activity, it was found that 
MnCl2, NaCl and CaCl2 ions contribute to increase the activity, however the 
optimal enzyme cofactors is manganese, since this achieves a greater increase 
in activity while  sodium and calcium only accounts for a slight increase in activity. 
 
It was found that Benzamidine, STI, Chymostatin and TPCK were the 
ones highest percentage of inhibition of the enzyme BmK 100%, 100%, 93% and 
82%, respectively. Benzamidine and STI are inhibitors of serine proteases and 
trypsin-like enzymes, TPCK is a serine protease inhibitor. The Chymostatin is a 
strong inhibitor of many proteases, particularly serine proteases of the 
chymotrypsin-like. Chymostatin and PMSF were those who had higher percent 
inhibition of the BmK enzyme. The Chymostatin is a strong inhibitor of many 
proteases, particularly chymotrypsin, serine proteases of the chymotrypsin-like, 
chymases and lysosomal cysteine proteases such as captesinas B, H and L. The 
results are quite informative to BmK enzyme, indicating that it belongs to the 
family of serine proteases of the chymotrypsin (Barret et al., 2013). 
For the test on the specific substrates, it was found that the enzyme has 
degraded only one substrate, with greater specificity with the Suc-Ala-Ala-Pro-
Phe-pNA substrate, these substrate is specific for chymotrypsin and cathepsin G, 
confirming again that BmK enzyme in question belongs to the family of serine 
proteases of the chymotrypsin. (Barrett et al., 2013) Serine proteases are 
characterized by the presence of a catalytic triad composed of the residues of the 
amino acids aspartic acid (electrophile), serine (nucleophile) and histidine (base). 
The serine acts as a very reactive residue (nucleophile) forming a covalent bond 
with the substrate. The optimum catalytic activity of these enzymes is set at pH 
values between 7 and 9 (Perona, et al., 1995). 
Through the fibrin plate assay it was possible to estimate the fibrinolytic 
activity of the BK enzyme from commercial Urokinase. Both enzymes were 
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applied to the fibrin plate, BmK was applied with a concentration of 15μg and Uk 
was applied with 5μ. The calculation of the activity constant was calculated and 
Urokinase activity is higher than BmK, as expected. Urokinase activity constant 
was 3.31 and BmK constant was 3.31 less 1.25 units than UK.  
With Urokinase we can see a faster digestion of fibrin by activation of 
plasminogen, in the other hand it’s known that is a very expensive enzyme and 
have some clinical disadvantages, after intravenous administration there is a 
significant risk of bleeding and allergic reaction (Yang, et al., 2012). Bmk showed 
its capacity of digest directly fibrin unlike the biggest part of commercial fibrinolytic 
enzymes that are plasminogen activators (t-PA). Also this bacillus sp. enzyme 
didn’t interfere with normal coagulation pathway and blood functionality as 
confirmed with aPPT and PT test, hemolytic test and fibrinogenolytic test. 
 
V Future Works 
The biggest part of thrombolytic agents such as Urokinadse, steptokinase, 
genetically tissue-type plasminogen activators (t-AP), have also been widely 
applied in thrombolytic treatments, but they seem not to be affective because of 
many undesirable side effects. To be specific, the patient may be vulnerable to 
resistance to reperfusion, occurrence of acute coronary reclusion, allergic 
reaction and bleeding complication (Bode, et al., 1996). Furthermore both 
streptokinase and urokinase dependent and act by the activation of plasminogen 
to plasmin (indirect action), making it important to direct the further research for 
the discovery of novel agents that are able to act directly on fibrin (Caramelli et 
al., 1992). The limited efficacy and undesired side effects of these thrombolytic 
agents pose problems for their clinical application. Much research is made in 
order to overcome these problems by seeking increasing the thrombolytic activity 
of the target or for improving targeting of these proteins on the clots.  
Therefore, the findings for new save and inexpensive fibrinolytic enzyme 
is very essential. BmK don’t interfere with normal coagulation pathway and blood 
functionality as confirmed with aPPT and PT test, hemolytic assay and 
fibrinogenolytic activity assay. This chymotrypsin-like protease demonstrated a 
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good activity in physiological conditions and its ability of digest directly fibrin 
without activation plasminogen. Future works in vivo with BmK would be an 
important step towards a new potential enzyme with pharmacological 
applications. 
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VII Annex 
 
Figure 1: Bacilli from traditional food (Kotb, 2012). 
 
Figure 2: Sources of microbial enzymes (Kotb, 2012). 
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Figure 3: Agar Casein Plates. plates were incubated 24hrs at 37 ºC. 
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Figure 4: Agarose Fibrin Plate. The plates were incubated 16 hrs at 37 ºC 
 
Figure 5: Hemolytic assay plate (CAN plate with sheep blood). Incubation for 6 
hrs at 37˚C. 
